Impact of PIK3CA mutation status on immune marker response and pCR in the WSG-ADAPT HER2+/HR+ phase II trial. This is an ASCO Meeting Abstract from the 2018 ASCO Annual Meeting I. This abstract does ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback